Three small-cap stocks grabbed attention this week with sharp gains driven by very different catalysts: a government contract, a clinical trial success, and a blank-check merger. The moves highlight how a single headline can dramatically move shares of smaller companies, which often have thinner trading and higher volatility than their large-cap peers.
Xos doubles on US Air Force deal
Electric vehicle maker Xos saw its stock more than double after announcing an agreement with the US Air Force to develop and deliver a deployable mobile charging system for electrified support equipment and vehicles. The deal is a credibility boost for the company, which focuses on commercial electric trucks and has been working to build a customer base beyond private fleets.
Investors treated the news as a significant validation of Xos's technology and its ability to win government contracts. Trading volume surged to 96.8 million shares, compared with a daily average of just over 3 million, underscoring the intense interest. For a small-cap stock, such a spike in volume often signals that institutional investors are taking notice, but it can also lead to sharp swings in both directions.
Amylyx climbs on phase 3 trial win
Amylyx Pharmaceuticals jumped 55% after reporting that its experimental drug Avexitide met the main goal in a late-stage (phase 3) clinical trial. The company is developing the treatment for a condition related to low blood sugar, and the positive result could pave the way for a regulatory submission.
For biotech investors, phase 3 results are a make-or-break moment. A win can send shares soaring, as seen here, while a failure can wipe out a large portion of a company's market value. Amylyx's gain reflects the market's assessment that the drug now has a clearer path to approval, though regulatory hurdles remain.
FORT Robotics SPAC plan values it at $556.6 million
FORT Robotics, a company that provides safety and security software for autonomous machines, announced plans to go public via a merger with a special purpose acquisition company (SPAC). The deal values FORT at $556.6 million. SPACs, also known as blank-check companies, raise money from investors and then merge with a private firm to take it public, often faster than a traditional IPO.
While SPAC activity has cooled from its peak a few years ago, deals still occur, especially for companies in emerging tech areas like robotics and automation. For FORT, the merger provides access to public capital and liquidity for early investors. For SPAC shareholders, the deal offers a chance to invest in a company that might otherwise be hard to reach.
What it means for investors
These three moves illustrate the potential rewards and risks of small-cap investing. On one hand, a single positive development can produce outsized gains. On the other, small caps are often more sensitive to news flow, and their shares can be volatile in both directions.
For everyday investors, the key takeaway is not to chase a stock after a big jump. Instead, consider whether the underlying business fundamentals support the new valuation. In the case of Xos, the Air Force deal is a promising sign, but the company still faces the challenge of scaling production and achieving profitability. Amylyx's trial win is encouraging, but the drug still needs regulatory approval and commercial success. FORT Robotics' SPAC deal gives it a public listing, but investors should examine the company's financials and growth prospects before diving in.
Also, remember that small-cap stocks can be more volatile than large-cap ones, and they may be less liquid, meaning it can be harder to buy or sell shares without affecting the price. Diversification remains a cornerstone of prudent investing, and a small allocation to small caps can be part of a balanced portfolio, but it's wise to avoid concentrating too much in any single stock.
As always, do your own research and consider consulting a financial advisor to align any investment with your goals and risk tolerance.
